Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058747 · ClinicalTrials.gov registry record · Phase 2
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™
A Phase 2 study, sponsored by Agenus.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00058747 is a Phase 2 study that was terminated before completion, run by Agenus. The registered enrollment target is 40 participants.
The verdict
NCT00058747, a Phase 2 study, was terminated before completion, sponsored by Agenus.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a Phase II, exploratory, open-label study of the investigational product AG-858, in patients who are cytogenetically positive after treatment with Gleevec. The trial will consist of three independent Phase II evaluations of patient groups according to their cytogenetic status as defined in the eligibility criteria (Eligibility Criteria 4a, 4b, and 4c).
Interventions
- DRUG Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058747
The ClinicalTrials.gov registry entry for NCT00058747 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™. is the first listed.
NCT00058747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058747 about?
NCT00058747 is a clinical study titled "AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™". This is a Phase II, exploratory, open-label study of the investigational product AG-858, in patients who are cytogenetically positive after treatment with Gleevec. The trial will consist of three independent Phase II evaluations of patient groups according to their cytogenetic status as defined in ...
What is the current status of trial NCT00058747?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2003-03. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00058747?
The interventions under investigation include: Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™. (DRUG).
Who is sponsoring clinical trial NCT00058747?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.